

Title (en)

CICLESONIDE FOR THE TREATMENT OF AIRWAY DISEASE IN HORSES

Title (de)

CICLESONIDE FÜR DIE BEHANDLUNG VON ATEMWEGSERKRANKUNGEN BEI PFERDEN

Title (fr)

CICLÉSONIDE POUR LE TRAITEMENT DE MALADIES DES VOIES RESPIRATOIRES CHEZ LES CHEVAUX

Publication

**EP 2934479 B1 20180919 (EN)**

Application

**EP 13811924 A 20131218**

Priority

- EP 12199302 A 20121221
- EP 2013077265 W 20131218
- EP 13811924 A 20131218

Abstract (en)

[origin: US2014179651A1] The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).

IPC 8 full level

**A61K 31/58** (2006.01); **A61K 9/00** (2006.01); **A61K 31/573** (2006.01); **A61P 11/00** (2006.01)

CPC (source: EP US)

**A61K 9/0073** (2013.01 - EP US); **A61K 9/0078** (2013.01 - EP US); **A61K 9/008** (2013.01 - US); **A61K 31/58** (2013.01 - EP US); **A61P 11/00** (2017.12 - EP)

Citation (examination)

FEI: "SUBSTANCE ACTIVITY BANNED SUBSTANCES", 4 April 2011 (2011-04-04), XP055296090, Retrieved from the Internet <URL:http://bahh.government.bg/uploads/File/Za\_biznesa/VMP/2011\_Equine\_Prohibited\_List.pdf> [retrieved on 20160817]

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

**US 2014179651 A1 20140626**; AR 094241 A1 20150722; AU 2013360691 A1 20150416; AU 2013360691 B2 20180308; AU 2018201642 A1 20180329; AU 2018201642 B2 20190131; BR 112015010842 A2 20170711; BR 112015010842 A8 20191001; BR 112015010842 B1 20210330; BR 122016029247 A2 20190820; CA 2888428 A1 20140626; CA 2888428 C 20210713; CY 1121115 T1 20191211; CY 2020015 I1 20201125; CY 2020015 I2 20210312; DK 2934479 T3 20181105; EP 2934479 A1 20151028; EP 2934479 B1 20180919; ES 2693779 T3 20181213; FR 20C1026 I1 20201002; HR P20181980 T1 20190125; HU S2000020 I1 20200728; IN 2894DEN2015 A 20150911; LT 2934479 T 20181227; LT PA2020511 I1 20200727; MA 38169 A1 20170131; MA 38169 B2 20210831; MX 2015007947 A 20151008; MX 368306 B 20190927; NO 2020014 I1 20200612; NZ 706573 A 20191129; PL 2934479 T3 20190228; PT 2934479 T 20181220; RS 57740 B1 20181231; SI 2934479 T1 20190131; US 10258634 B2 20190416; US 10441597 B2 20191015; US 2015313918 A1 20151105; US 2017079988 A1 20170323; US 2018153907 A1 20180607; US 9918995 B2 20180320; WO 2014096115 A1 20140626; ZA 201502288 B 20190925

DOCDB simple family (application)

**US 201314132580 A 20131218**; AR P130104978 A 20131220; AU 2013360691 A 20131218; AU 2018201642 A 20180307; BR 112015010842 A 20131218; BR 122016029247 A 20131218; CA 2888428 A 20131218; CY 181101189 T 20181109; CY 2020015 C 20200629; DK 13811924 T 20131218; EP 13811924 A 20131218; EP 2013077265 W 20131218; ES 13811924 T 20131218; FR 20C1026 C 20200626; HR P20181980 T 20181126; HU S2000020 C 20200629; IN 2894DEN2015 A 20150408; LT 13811924 T 20131218; LT PA2020511 C 20200618; MA 38169 A 20131218; MX 2015007947 A 20131218; NO 2020014 C 20200612; NZ 70657313 A 20131218; PL 13811924 T 20131218; PT 13811924 T 20131218; RS P20181190 A 20131218; SI 201331266 T 20131218; US 201314654009 A 20131218; US 201615292765 A 20161013; US 201815889307 A 20180206; ZA 201502288 A 20150407